Shilpa Medicare Limited

Shilpa Medicare Limited

Shilpa Medicare Limited has received Europe GMP Approval for its Unit 4 in Jadcherla, Telangana, following a successful inspection by AGES, Austria.

Shilpa Medicare Limited

Shilpa Medicare Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, regarding the details of securities dematerialized or rematerialized during the period.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Shilpa Medicare Limited

Shilpa Medicare Limited has been assigned an Environmental, Social and Governance (ESG) score of 'Crisil ESG 59' by CRISIL ESG Ratings, based on disclosures for fiscal 2026 and other publicly available data.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about a scheduled investor conference on September 28, 2026, where the company's officials will meet with investors and analysts in Mumbai.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about USFDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division, Hyderabad. The inspection concluded with one procedural observation, which was neither a repeat observation nor related to data integrity.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange regarding voting results of the Annual General Meeting held on September 11, 2026. The company has reported the results of the remote e-voting and electronic voting at the AGM, which were carried out in a fair and transparent manner.

Shilpa Medicare Limited

Shilpa Medicare Limited has received final approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) for grant of marketing authorization for OERIS™ (Ondansetron Extended-Release Injection, 100 mg/mL).

Shilpa Medicare Limited

Shilpa Medicare Limited held its 39th Annual General Meeting on September 11, 2026, through Video Conferencing. The meeting was attended by 48 members, and the resolutions were passed with the requisite quorum. The company declared a dividend of 0.60 per equity share for the financial year ended March 31, 2026. The meeting was concluded at 11:57 a.m.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about the initiation of Corporate Insolvency Resolution Process (CIRP) against its wholly-owned subsidiary FTF Pharma Private Limited due to an alleged operational debt of ₹2,18,03,319/- claimed by Immacule Lifesciences Private Limited.

Shilpa Medicare Limited

Shilpa Medicare Limited has dispatched a letter to shareholders whose email addresses are not registered with the company, registrar, and transfer agent, providing a web-link to the Annual Report for the Financial Year 2025-26 and Notice of the 39th Annual General Meeting.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about a voluntary recall of 27,923 vials of chemotherapy drug in the US due to atypical discoloration. The recall has been classified by the US FDA as a Class II (hospital level) recall. The company does not foresee any material impact on its financial position, operations, or other affairs.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about Dividend Updates. The company has recommended a Dividend of Re. 0.60/- per Equity Share for the financial year ended March 31, 2026. The Board has fixed Friday, 4 September, 2026, as the record date for determining entitlement of members to receive the Final dividend.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding notice of the 39th Annual General Meeting, e-voting and other information to the shareholders.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026. The meeting will consider and pass various resolutions, including the appointment of a director, payment of commission to the cost auditors, and ratification of remuneration.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about the transcript of the Q1FY27 Conference call held on August 05, 2026. The company's management discussed their first quarter FY27 results, highlighting their operational leverage, debt reduction, and growth in their API and Formulation divisions.

Shilpa Medicare Limited

Shilpa Medicare Limited has informed the Exchange about the link of recording of their Q1/FY2026-27 Conference Call held on 5th August, 2026. The audio recording is available on their website.

Shilpa Medicare Limited

Shilpa Medicare Limited has announced its 1QFY27 earnings, with revenue and EBITDA growth of 43% and 42% YoY respectively, driven by strong performance across its three key verticals. The company has also announced a credit rating upgrade to AA- and has partnered with Gate2Brain for a novel asset.

Shilpa Medicare Limited

Shilpa Medicare Limited has announced the record date for the payment of final dividend for the financial year 2025-26 as 04-Sep-2026.

Shilpa Medicare Limited

Shilpa Medicare Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 18,904 lakhs and net sales/income from operations at Rs. 16,592 lakhs. The company has also announced the appointment of a new whole-time director, Mr. Sharath Reddy Kalakota, and the payment of remuneration to a non-executive director. Additionally, the company has informed about a proposed strategic long-term equity partnership with Gate2Brain and the schedule for the 39th Annual General Meeting (AGM).